Clinical Trials
18 trialsNCT04566393 2026-06-04
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
xCures
Available
NCT06797362 2026-05-28
Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors
Nuvalent Inc.
Available
NCT07601399 2026-05-22
An EAP Treatment Protocol of Zipalertinib
Taiho Oncology, Inc.
Available
NCT06751524 2026-05-15
Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval
Agenus Inc.
Available
NCT06834074 2026-05-14
NVL-655-EAP
Nuvalent Inc.
Available
NCT04830202 2026-05-13
Expanded Access to Telisotuzumab Vedotin
AbbVie
Temporarily not available
NCT07535359 2026-05-06
Medical Access Program for Ifinatamab Deruxtecan in 3L+ Pretreated Extensive-stage Small Cell Lung Cancer
Daiichi Sankyo
Available
NCT05100134 2026-04-01
Managed Access Programs for LDK378, Ceritinib
Novartis
No longer available
NCT04741789 2026-03-16
Managed Access Programs for INC280, Capmatinib
Novartis
No longer available
NCT04091295 2026-03-04
BLESSED: Expanded Access for DNG64-CAR-V for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of Breast
Aveni Foundation
Available
NCT07310277 2026-01-29
Expanded Access to ABBV-706
AbbVie
Available
NCT03756311 2026-01-23
Expanded Access to NanoPac
NanOlogy, LLC
No longer available
NCT06841874 2025-12-24
Tale EAP
Nuvation Bio Inc.
No longer available
NCT06132191 2025-11-20
Expanded Access Use of Cemiplimab in Patients With Solid Tumors
Regeneron Pharmaceuticals
Approved for marketing
NCT04667234 2025-08-13
Expanded Access of Sotorasib
Amgen
No longer available
NCT06872489 2025-07-23
Expanded Access Protocol for the Use of SL-28 in the Treatment of Advanced Solid Tumors
Second Life Therapeutics
Available
NCT06279728 2025-07-03
Medical Access Program for Datopotamab Deruxtecan in EGFRm NSCLC Patients
Daiichi Sankyo
Approved for marketing
NCT04599712 2025-06-13
Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung Cancer
Janssen Research & Development, LLC
Approved for marketing